· Trials · Trials Desk
REDEFINE 4 failed to demonstrate non-inferiority of CagriSema vs tirzepatide, capping CagriSema's commercial ceiling and validating dual GLP-1/GIP agonism. NCT06131437, NCT05669755.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.